LifeMD price target lowered to $13 from $14 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on LifeMD (LFMD) to $13 from $14 and keeps a Buy rating on the shares. The company reported a Q2 miss and reduced its outlook, the analyst tells investors in a research note.